193. Prader-Willi syndrome Clinical trials / Disease details

Clinical trials : 113 / Drugs : 111 - (DrugBank : 26) / Drug target genes : 48 - Drug target pathways : 102

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00399893 (ClinicalTrials.gov)	December 2006	14/11/2006	Octreotide Therapy in Children and Young Adults With Prader-Willi Syndrome (PWS)	Investigation of the Developmental, Nutritional and Hormonal Regulation of Ghrelin in Children and Young Adults With Prader-Willi Syndrome (PWS): Octreotide Intervention Sub-study	Prader-Willi Syndrome	Drug: Octreotide;Drug: Placebo	Duke University	National Institutes of Health (NIH);National Center for Research Resources (NCRR);Novartis	Terminated	5 Years	21 Years	All	5	N/A	United States
2	NCT01613495 (ClinicalTrials.gov)	August 2005	13/4/2011	Ghrelin Suppression by Octreotide in Prader-Willi	Ghrelin Suppression by Sandostatin LAR® Depot (Octreotide Acetate for Injectable Suspension) in Patients With Prader-Willi Syndrome	Prader Willis Syndrome	Drug: Placebo;Drug: Octreotide	Oregon Health and Science University	NULL	Active, not recruiting	18 Years	N/A	Male	2	N/A	NULL